Vitrolife AB Stock

Equities

VITR

SE0011205202

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm 11:29:33 2024-04-12 am EDT 5-day change 1st Jan Change
189.8 SEK -0.11% Intraday chart for Vitrolife AB +2.98% -2.52%
Sales 2023 3.51B 323M Sales 2024 * 3.79B 348M Capitalization 25.7B 2.36B
Net income 2023 -3.85B -354M Net income 2024 * 603M 55.4M EV / Sales 2023 7.86 x
Net Debt 2023 1.23B 113M Net Debt 2024 * 571M 52.45M EV / Sales 2024 * 6.94 x
P/E ratio 2023
-6.85 x
P/E ratio 2024 *
43.7 x
Employees 1,123
Yield 2023
0.51%
Yield 2024 *
0.62%
Free-Float 55.39%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.11%
1 week+2.98%
Current month-5.57%
1 month-5.76%
3 months+7.29%
6 months+36.74%
Current year-2.52%
More quotes
1 week
180.50
Extreme 180.5
194.80
1 month
180.50
Extreme 180.5
205.40
Current year
162.90
Extreme 162.9
205.40
1 year
123.90
Extreme 123.9
244.20
3 years
123.90
Extreme 123.9
585.00
5 years
112.30
Extreme 112.3
585.00
10 years
18.00
Extreme 18
585.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-07-31
Director of Finance/CFO 54 21-12-31
Chairman 68 15-05-06
Members of the board TitleAgeSince
Director/Board Member 53 19-05-01
Chairman 68 15-05-06
Director/Board Member 64 18-04-26
More insiders
Date Price Change Volume
24-04-12 189.8 -0.11% 78,062
24-04-11 190 +2.59% 98,859
24-04-10 185.2 -0.54% 41,944
24-04-09 186.2 -0.37% 62,903
24-04-08 186.9 +1.41% 78,010

Delayed Quote Nasdaq Stockholm, April 12, 2024 at 11:29 am EDT

More quotes
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
189.8 SEK
Average target price
248.3 SEK
Spread / Average Target
+30.84%
Consensus